Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Radiopharm Theranostics L...

    NASDAQ: RADX · Real-Time Price · USD
    5.08
    -0.04 (-0.84%)
    At close: Jun 17, 2025, 3:39 PM
    5.27
    3.64%
    After-hours: Jun 17, 2025, 07:58 PM EDT

    Radiopharm Theranostics Statistics

    Share Statistics

    Radiopharm Theranostics has - shares outstanding. The number of shares has increased by null% in one year.

    Shares Outstanding

    n/a
    		 n/a

    Shares Change (YoY)

    n/a
    		 n/a

    Shares Change (QoQ)

    n/a
    		 n/a

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 1,394

    FTD / Avg. Volume

    n/a
    		 4.87%

    Short Selling Information

    The latest short interest is 39.15K, so 0% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 39.15K

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 1.97

    Valuation Ratios

    The PE ratio is -0.71 and the forward PE ratio is null. Radiopharm Theranostics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.71

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 114.19

    Forward PS

    n/a
    		 2.3

    PB Ratio

    n/a
    		 1.22

    P/FCF Ratio

    n/a
    		 -1.49

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Radiopharm Theranostics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.3, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 1.3

    Quick Ratio

    n/a
    		 1.3

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 -56.96

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 n/a

    Employee Count

    n/a
    		 undefined

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 96.36K

    Effective Tax Rate

    n/a
    		 -0.2%

    Stock Price Statistics

    The stock price has increased by null% in the last 52 weeks. The beta is 0.84, so Radiopharm Theranostics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.84

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 4.41

    200-Day Moving Average

    n/a
    		 n/a

    Relative Strength Index (RSI)

    n/a
    		 56.45

    Average Volume (20 Days)

    n/a
    		 28,633

    Income Statement

    In the last 12 months, Radiopharm Theranostics had revenue of 299.23K and earned -47.95M in profits. Earnings per share was 0.

    Revenue

    n/a
    		 299.23K

    Gross Profit

    n/a
    		 299.23K

    Operating Income

    n/a
    		 -36.62M

    Net Income

    n/a
    		 -47.95M

    EBITDA

    n/a
    		 -44.08M

    EBIT

    n/a
    		 -47.21M

    Earnings Per Share (EPS)

    n/a
    		 0
    Full Income Statement

    Balance Sheet

    The company has 18.58M in cash and 0 in debt, giving a net cash position of 18.58M.

    Cash & Cash Equivalents

    n/a
    		 18.58M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -111.34M

    Total Assets

    n/a
    		 n/a

    Working Capital

    n/a
    		 n/a
    Full Balance Sheet

    Cash Flow

    Operating Cash Flow

    n/a
    		 n/a

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -22.98M

    FCF Per Share

    n/a
    		 -0.06
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -12238.44% and -16024.28%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -12238.44%

    Pretax Margin

    n/a
    		 -15992.07%

    Profit Margin

    n/a
    		 -16024.28%

    EBITDA Margin

    n/a
    		 -14732.44%

    EBIT Margin

    n/a
    		 -12238.44%

    FCF Margin

    n/a
    		 -7678.4%

    Dividends & Yields

    RADX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RADX is $13.5, which is 163.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $13.5

    Price Target Difference

    n/a
    		 163.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 n/a

    Piotroski F-Score

    n/a
    		 n/a

    Add to Watchlist